+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

The effect of tamoxifen on the risk and prognosis of endometrial cancer following breast cancer



The effect of tamoxifen on the risk and prognosis of endometrial cancer following breast cancer



American Journal of Epidemiology 147(11 SUPPL ): S64, June 1




(PDF emailed within 1 workday: $29.90)

Accession: 033784817

Download citation: RISBibTeXText



Related references

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356(9233): 881-887, 2000

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet (North American Edition) 356(9233): 881-887, 9 September, 2000

Absence of correlation between risk factors for endometrial cancer and the presence of tamoxifen-associated endometrial polyps in postmenopausal patients with breast cancer. European Journal of Cancer 36 Suppl 4: S40-S42, 2000

Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone). Evidence-Based Medicine 15(4): 122-122, 2010

Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?. Obstetrics and Gynecology 105(1): 218; Author Reply 218-9, 2004

Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer. Surgery Today 36(1): 41-46, 2005

Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. Journal of the National Cancer Institute 97(5): 375-384, 2005

The combined effects of ERT, obesity and tamoxifen therapy for breast cancer on endometrial cancer risk. European Journal of Cancer 34(SUPPL 4): S46, 1998

Risk of endometrial cancer in breast cancer patients under long-term adjuvant treatment with tamoxifen. Tumori 84(1): 21-23, 1998

Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet (North American Edition) 343(8895): 448-452, 1994

Tamoxifen therapy for breast cancer and endometrial cancer risk. Journal of the National Cancer Institute 91(19): 1654-1662, 1999

Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer. Anticancer Research 16(5b): 3241-3246, 1996

Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. International Journal of Cancer 100(3): 337-341, 2002

Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients. European Journal of Surgical Oncology 40(10): 1237-1244, 2015

Suppression of Estrogenic Activity by Medroxyprogesterone Acetate in Tamoxifen-treated Patients after Surgery for Breast Cancer to Reduce the Risk of Endometrial Cancer Development. Breast Cancer 3(1): 25-31, 1996